

INVESTOR NEWSLETTER

FEBRUARY 2023

February 2023

ADVANCING OUR PIPELINE



Meet Navitor: Key Add to Structural Heart Portfolio

U.S. approval of Navitor solidifies Abbott's competitiveness in the TAVI market.



Poised for Growth Amid Uncertain Environment

Abbott Chairman and CEO on product pipeline, biowearables and COVID testing.



Partnerships Changing Diabetes Management

Abbott is connecting its tech with major insulin delivery systems.

CONTINUED RESILIENCY



Abbott Q4 Earnings

Key numbers and highlights from the company's fourth quarter and full year.

For the latest on what's happening at Abbott, visit us at www.abbottinvestor.com or follow us on [Twitter](#) and [LinkedIn](#).



[UNSUBSCRIBE](#) | [PRIVACY POLICY](#)

©2023 Abbott. All Rights Reserved.

Abbott | 100 Abbott Park Road | Abbott Park, IL 60044 | (224) 667-6100